3 completed, 3 recruiting, 2 terminated. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 3, Recruiting 3, Terminated 2 |
| Phase 2 | 2 | Terminated 2 |
Follow PharmaEngine: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors PEP08 - Advanced Solid Tumor, Solid Tumors | Phase 1 | Recruiting | PharmaEngine | 40 | 2025-08-26 | 2026-02-13 |
| A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors PEP07 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Recruiting | PharmaEngine | 54 | 2024-03-27 | 2024-11-07 |
| A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer PEP07 - Acute Myeloid Leukemia, Lymphoma, Mantle-Cell | Phase 1 | Recruiting | PharmaEngine | 32 | 2023-07-17 | 2025-07-31 |
| Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors Nanoliposomal Irinotecan - Refractory Solid Tumors | Phase 1 | Completed | PharmaEngine | 44 | 2019-03-05 | 2023-11-18 |
| A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer PEP503, Cisplatin, Radiotherapy - Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | PharmaEngine | 12 | 2016-10-11 | 2022-01-11 |
| A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer PEP503, 5-fluorouracil, capecitabine - Rectal Cancer | Phase 1 / Phase 2 | Terminated | PharmaEngine | 32 | 2015-06-01 | 2022-01-11 |
| Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy PEP02 - Metastatic Colorectal Cancer | Phase 1 | Completed | PharmaEngine | 18 | 2009-06-01 | 2017-04-06 |
| A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors PEP02, 5-FU, LV - Solid Tumor | Phase 1 | Completed | PharmaEngine | 16 | 2006-01-01 | 2016-08-30 |
Colorectal Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Mantle-Cell (1) · Neoplasm Metastasis (1) · Rectal Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Fluorouracil (2) · Radiotherapy (2) · irinotecan sucrosofate (2) · Capecitabine (1) · Cisplatin (1) · Leucovorin (1) · trifluridine tipiracil drug combination (1)
Taiwan (7) · Australia (2)
Cheng-Hsu Wang, M.D. (1) · Chia-Chi Lin, MD (1) · Hsin-An Hou, M.D. (1) · Jwa-Yuan Wang, phD (1)